Collection to commercialization: Is standardization the bottleneck or breakthrough for cell and gene therapy

Cell therapy developers face a growing challenge in scaling programs to meet global trial complexity while satisfying increasingly urgent demands from investors and regulators. Investors want evidence of commercial readiness from the earliest stages, while regulators are signaling a heightened focus on standardization across multi-site trials. Together, these pressures are reshaping the way therapeutic sponsors and service providers must plan their programs.

In this panel discussion, leaders from across the cell therapy ecosystem will share perspectives on how to anticipate these pressures and build strategies that set programs up for long-term success.